Identification of Novel Malaria Transmission-Blocking Vaccine Candidates.
Front Cell Infect Microbiol
; 11: 805482, 2021.
Article
in English
| MEDLINE | ID: covidwho-1581379
ABSTRACT
Control measures have significantly reduced malaria morbidity and mortality in the last two decades; however, the downward trends have stalled and have become complicated by the emergence of COVID-19. Significant efforts have been made to develop malaria vaccines, but currently only the RTS,S/AS01 vaccine against Plasmodium falciparum has been recommended by the WHO, for widespread use among children in sub-Saharan Africa. The efficacy of RTS,S/AS01 is modest, and therefore the development of more efficacious vaccines is still needed. In addition, the development of transmission-blocking vaccines (TBVs) to reduce the parasite transmission from humans to mosquitoes is required toward the goal of malaria elimination. Few TBVs have reached clinical development, and challenges include low immunogenicity or high reactogenicity in humans. Therefore, novel approaches to accelerate TBV research and development are urgently needed, especially novel TBV candidate discovery. In this mini review we summarize the progress in TBV research and development, novel TBV candidate discovery, and discuss how to accelerate novel TBV candidate discovery.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Malaria, Falciparum
/
Malaria Vaccines
/
COVID-19
/
Malaria
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Animals
/
Child
/
Humans
Language:
English
Journal:
Front Cell Infect Microbiol
Year:
2021
Document Type:
Article
Affiliation country:
Fcimb.2021.805482
Similar
MEDLINE
...
LILACS
LIS